Abstract

BACKGROUND: With the success of kidney transplantation, liver disease has emerged as an important cause of morbidity and mortality in kidney recipients. OBJECTIVE: To determine the impact of hepatitis B virus (HBV) infection on patients and graft survival in both short- and long-terms. METHODS: 99 renal transplant patients infected with HBV on follow-up in two major transplant centers were included in a retrospective study. These patients were grafted between 1986 and 2005 and divided into two groups: (1) those only positive for hepatitis B surface antigen (HBsAg) and (2) those who were also positive for hepatitis C virus antibodies (HCV Ab). RESULTS: There were 88 patients with HBsAg(+) and 11 with both HBsAg(+) and HCV Ab(+). The mean+/-SD age of patients was 38.8+/-13.2 years, and the median follow-up after transplantation was 19 months. Although not significant, the allograft survival rate in the first group (HBV(+)) was better compared to that in the second group (HBV(+) and HCV(+)); 1, 5 and 10 years graft survival rates were 91, 77 and 62 in the first group and 70, 56 and 28 in the second group, respectively (P=0.07). The overall mortality was 5 (4 of 88) in the first and 27 (3 of 11) in the second group (P=0.02). CONCLUSION: Renal allograft recipients with HBV and HCV infections has a poor survival rate compared to patients with only HBV infection. However, there is no significant difference in terms of renal graft survival between the two groups.